QIAGEN N.V. (QGEN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Mar 20, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the QGEN SEC filings page.
QIAGEN N.V. (QGEN) reported $2.1B in revenue for fiscal year 2025, up 5.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Qiagen’s 2025 recovery restored margins and earnings, but financing shifted toward more debt while cash generation remained steadier than profits.
The 2024 profit collapse was not matched by cash: net income fell to$83.6M while operating cash flow remained$673.6M , then 2025 net income recovered to$424.9M as operating cash flow eased to$654.3M . That combination points to unusually volatile reported earnings in 2024, while cash conversion was less volatile than accounting profit.
Sales changed little, yet gross margin recovered from
Current ratio rose from 1.9x in FY2024 to 3.9x in FY2025. Yet long-term debt nearly doubled to
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of QIAGEN N.V.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
QIAGEN N.V. has an operating margin of 22.3%, meaning the company retains $22 of operating profit per $100 of revenue. This strong profitability earns a score of 75/100, reflecting efficient cost management and pricing power. This is up from 4.9% the prior year.
QIAGEN N.V.'s revenue grew 5.7% year-over-year to $2.1B, a solid pace of expansion. This earns a growth score of 42/100.
QIAGEN N.V. has a moderate D/E ratio of 0.44. This balance of debt and equity financing earns a leverage score of 43/100.
With a current ratio of 3.90, QIAGEN N.V. holds $3.90 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 87/100.
QIAGEN N.V. converts 21.7% of revenue into free cash flow ($453.3M). This strong cash generation earns a score of 88/100.
QIAGEN N.V.'s ROE of 11.3% shows moderate profitability relative to equity, earning a score of 54/100. This is up from 2.3% the prior year.
QIAGEN N.V. scores 3.74, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($9.5B) relative to total liabilities ($2.5B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
QIAGEN N.V. passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, QIAGEN N.V. generates $1.54 in operating cash flow ($654.3M OCF vs $424.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
QIAGEN N.V. earns $14.01 in operating income for every $1 of interest expense ($465.9M vs $33.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
QIAGEN N.V. held $839.0M in cash against $1.7B in long-term debt as of Q4 2025.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
QGEN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
QGEN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q4'2420-F | Q4'2310-K | Q4'2210-K | Q4'2110-K | Q4'2010-K | Q4'1910-K | Q4'1810-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.3B+10.4% | $5.7B-7.0% | $6.1B-2.7% | $6.3B+2.3% | $6.1B+4.7% | $5.9B+12.1% | $5.2B-8.9% | $5.7B+14.1% |
| Current Assets | $2.0B+1.8% | $2.0B-8.7% | $2.1B-10.3% | $2.4B+13.5% | $2.1B+29.9% | $1.6B+3.4% | $1.6B-27.1% | $2.2B+30.8% |
| Cash & Equivalents | $839.0M+26.4% | $663.6M-0.7% | $668.1M-8.6% | $730.7M-17.0% | $880.5M+47.2% | $598.0M-4.1% | $623.6M-46.2% | $1.2B+76.2% |
| Short-Term Investments | $259.9M-46.9% | $489.4M+25.6% | $389.7M-43.3% | $687.6M+272.1% | $184.8M+57.6% | $117.2M-9.5% | $129.6M-44.8% | $234.6M-34.7% |
| Inventory | $301.9M+8.1% | $279.3M-29.9% | $398.4M+11.3% | $358.0M+9.3% | $327.5M+12.5% | $291.2M+70.6% | $170.7M+4.8% | $162.9M+4.5% |
| Accounts Receivable | $402.6M+15.3% | $349.3M-8.5% | $381.9M+18.0% | $323.8M-10.6% | $362.1M-4.8% | $380.5M-1.2% | $385.1M+9.5% | $351.6M+6.8% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $2.7B+11.3% | $2.4B-2.0% | $2.5B+5.2% | $2.4B+0.1% | $2.4B-0.6% | $2.4B+10.4% | $2.1B+1.5% | $2.1B+4.8% |
| Total Liabilities | $2.5B+17.9% | $2.1B-8.0% | $2.3B-18.2% | $2.8B-7.5% | $3.1B-0.7% | $3.1B+13.8% | $2.7B-13.3% | $3.1B+24.7% |
| Current Liabilities | $512.1M-50.9% | $1.0B-3.5% | $1.1B+10.8% | $974.5M-35.8% | $1.5B+165.2% | $572.2M-39.9% | $951.3M-2.1% | $972.2M+199.3% |
| Non-Current Liabilities | $2.0B+84.3% | $1.1B-12.0% | $1.2B-33.5% | $1.8B+20.5% | $1.5B-38.7% | $2.5B+43.0% | $1.7B-18.4% | $2.1B-1.5% |
| Long-Term Debt | $1.7B+97.0% | $839.7M-8.9% | $921.8M-37.4% | $1.5B+34.5% | $1.1B-41.8% | $1.9B+32.3% | $1.4B-15.0% | $1.7B-5.0% |
| Total Equity | $3.8B+5.9% | $3.6B-6.3% | $3.8B+9.8% | $3.5B+12.0% | $3.1B+10.7% | $2.8B+10.3% | $2.5B-3.7% | $2.6B+3.7% |
| Retained Earnings | $2.7B+12.3% | $2.4B-0.4% | $2.5B+13.7% | $2.2B+20.6% | $1.8B+35.4% | $1.3B+12.3% | $1.2B-14.6% | $1.4B+10.6% |
QGEN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
QGEN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| QIAGEN N.V. QGEN | FY2025 | $2.1B | $424.9M | 20.3% | $9.5B | 65/100 |
| Revvity, Inc. RVTY | FY2025 | $2.9B | $241.2M | 8.5% | $16.9B | 51/100 |
| Charles River Laboratories International, Inc. CRL | FY2025 | $4.0B | -$144.3M | -3.6% | $13.9B | 40/100 |
| Guardant Health, Inc. GH | FY2025 | $982.0M | -$416.3M | -42.4% | $23.9B | 63/100 |
| RadNet, Inc. RDNT | FY2025 | $2.0B | -$18.6M | -0.9% | $5.5B | 44/100 |
| Sotera Health Company SHC | FY2025 | $1.2B | $77.9M | 6.7% | $5.2B | 57/100 |
Where QIAGEN N.V. Ranks
Frequently Asked Questions
What is QIAGEN N.V.'s annual revenue?
QIAGEN N.V. (QGEN) reported $2.1B in total revenue for fiscal year 2025. This represents a 5.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is QIAGEN N.V.'s revenue growing?
QIAGEN N.V. (QGEN) revenue grew by 5.7% year-over-year, from $2.0B to $2.1B in fiscal year 2025.
Is QIAGEN N.V. profitable?
Yes, QIAGEN N.V. (QGEN) reported a net income of $424.9M in fiscal year 2025, with a net profit margin of 20.3%.
What is QIAGEN N.V.'s EBITDA?
QIAGEN N.V. (QGEN) had EBITDA of $659.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does QIAGEN N.V. have?
As of fiscal year 2025, QIAGEN N.V. (QGEN) had $839.0M in cash and equivalents against $1.7B in long-term debt.
What is QIAGEN N.V.'s gross margin?
QIAGEN N.V. (QGEN) had a gross margin of 62.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is QIAGEN N.V.'s operating margin?
QIAGEN N.V. (QGEN) had an operating margin of 22.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is QIAGEN N.V.'s net profit margin?
QIAGEN N.V. (QGEN) had a net profit margin of 20.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Does QIAGEN N.V. pay dividends?
Yes, QIAGEN N.V. (QGEN) paid $0.25 per share in dividends during fiscal year 2025.
What is QIAGEN N.V.'s return on equity (ROE)?
QIAGEN N.V. (QGEN) has a return on equity of 11.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is QIAGEN N.V.'s free cash flow?
QIAGEN N.V. (QGEN) generated $453.3M in free cash flow during fiscal year 2025. This represents a -10.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is QIAGEN N.V.'s operating cash flow?
QIAGEN N.V. (QGEN) generated $654.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are QIAGEN N.V.'s total assets?
QIAGEN N.V. (QGEN) had $6.3B in total assets as of fiscal year 2025, including both current and long-term assets.
What are QIAGEN N.V.'s capital expenditures?
QIAGEN N.V. (QGEN) invested $201.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does QIAGEN N.V. spend on research and development?
QIAGEN N.V. (QGEN) invested $187.5M in research and development during fiscal year 2025.
What is QIAGEN N.V.'s current ratio?
QIAGEN N.V. (QGEN) had a current ratio of 3.90 as of fiscal year 2025, which is generally considered healthy.
What is QIAGEN N.V.'s debt-to-equity ratio?
QIAGEN N.V. (QGEN) had a debt-to-equity ratio of 0.44 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is QIAGEN N.V.'s return on assets (ROA)?
QIAGEN N.V. (QGEN) had a return on assets of 6.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is QIAGEN N.V.'s P/E ratio?
QIAGEN N.V. (QGEN) trades at 22.3x earnings, its market capitalization divided by net income of $424.9M net income, FY2025. The market capitalization is $9.5B as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is QIAGEN N.V.'s price-to-sales ratio?
QIAGEN N.V. (QGEN) trades at 4.5x sales, its market capitalization divided by revenue of $2.1B revenue, FY2025. The market capitalization is $9.5B as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is QIAGEN N.V.'s Altman Z-Score?
QIAGEN N.V. (QGEN) has an Altman Z-Score of 3.74, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is QIAGEN N.V.'s Piotroski F-Score?
QIAGEN N.V. (QGEN) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are QIAGEN N.V.'s earnings high quality?
QIAGEN N.V. (QGEN) has an earnings quality ratio of 1.54x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can QIAGEN N.V. cover its interest payments?
QIAGEN N.V. (QGEN) has an interest coverage ratio of 14.01x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is QIAGEN N.V.?
QIAGEN N.V. (QGEN) scores 65 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.